ALNY

Alnylam Pharmaceuticals, Inc.

158.69 USD
+1.04 (+0.66%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Alnylam Pharmaceuticals, Inc. stock is down -11.65% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 19 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 44% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 18:26 19 Jul, 2024 135.00 PUT 19 470
22 Feb 19:24 19 Dec, 2025 125.00 CALL 15 0
23 Feb 14:38 19 Dec, 2025 220.00 CALL 10 0
26 Feb 20:10 20 Sep, 2024 175.00 PUT 10 4
26 Feb 20:10 20 Sep, 2024 185.00 PUT 7 4
26 Feb 20:25 20 Sep, 2024 150.00 CALL 14 169
26 Feb 20:25 20 Sep, 2024 200.00 CALL 100 323
26 Feb 20:25 20 Sep, 2024 150.00 CALL 25 169
26 Feb 20:27 20 Sep, 2024 200.00 CALL 16 323
26 Feb 20:52 19 Jul, 2024 135.00 PUT 20 490

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

  • Cantor Fitzgerald
    Fri Feb 23, 12:07
    hold
    confirm
  • RBC Capital
    Wed Feb 21, 09:51
    buy
    confirm
  • Cantor Fitzgerald
    Tue Feb 20, 12:29
    hold
    confirm
  • RBC Capital
    Tue Feb 20, 10:20
    buy
    confirm
  • Wells Fargo
    Fri Feb 16, 13:45
    hold
    confirm
  • Citigroup
    Fri Feb 16, 12:02
    buy
    confirm
  • RBC Capital
    Fri Feb 16, 11:51
    buy
    confirm
  • Chardan Capital
    Fri Feb 16, 08:12
    buy
    confirm
  • Goldman Sachs
    Fri Feb 16, 06:17
    hold
    downgrade
  • Needham
    Thu Feb 15, 13:26
    buy
    confirm
  • Cantor Fitzgerald
    Thu Feb 15, 09:16
    hold
    confirm
  • Wolfe Research
    Thu Feb 15, 06:52
    hold
    initial
  • RBC Capital
    Wed Feb 14, 10:00
    buy
    confirm
  • Morgan Stanley
    Tue Feb 13, 12:30
    hold
    confirm
  • Cantor Fitzgerald
    Mon Feb 12, 12:43
    hold
    confirm
  • JP Morgan
    Thu Feb 1, 09:15
    hold
    confirm